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Fas induces massive apoptosis in T cells after repeated in vitro T cell receptor (TCR) 
stimulation and is critical for lymphocyte homeostasis in Fas-deficient (lpr) mice. 
Although the in  vitro Fas apoptotic mechanism has been defined, there is a large 
conceptual gap between this in  vitro phenomenon and the pathway that leads to 
in vivo development of lymphadenopathy and autoimmunity. A striking abnormality in 
lpr mice is the excessive proliferation of CD4+ and CD8+ T cells, and more so of the 
double-negative TCR+CD4−CD8−B220+ T cells. The basis of lpr T cell hyperproliferation 
remains elusive, as it cannot be explained by Fas-deficient apoptosis. T cell-directed 
p21 overexpression reduces hyperactivation/hyperproliferation of all lpr T cell subtypes 
and lymphadenopathy in lpr mice. p21 controls expansion of repeatedly stimulated 
T  cells without affecting apoptosis. These results confirm a direct link between 
hyperactivation/hyperproliferation, autoreactivity, and lymphadenopathy in lpr mice 
and, with earlier studies, suggest that Fas apoptosis-independent pathways control 
lpr T cell hyperproliferation. lpr T cell hyperproliferation could be an indirect result of the 
defective apoptosis of repeatedly stimulated lpr T cells. Nonetheless, in this perspective, 
we argue for an alternative setting, in which lack of Fas would directly cause lpr T cell 
hyperactivation/hyperproliferation in vivo. We propose that Fas/Fas ligand (FasL) acts 
as an activation inhibitor of recurrently stimulated T cells, and that its disruption causes 
overexpansion of T cells in lpr mice. Research to define the underlying mechanism of 
this Fas/FasL effect could resolve the phenotype of lpr mice and lead to therapeutics for 
related human syndromes.
Keywords: Fas, p21, memory t cells, hyperproliferation, double-negative t cells, lupus autoimmunity, alternative 
functions, hyperactivation
Fas-DePeNDeNt APOPtOsis OF t ceLLs
Homeostasis regulates total lymphocyte number by balancing cell growth and death. Programmed 
cell death, referred to as apoptosis, eliminates activated or autoreactive lymphocytes and is thus 
important in immune system homeostasis. Interaction of Fas (CD95), a member of the tumor necro-
sis factor receptor family, with its ligand [(Fas ligand (FasL)] after in vitro recurrent T cell receptor 
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(TCR) triggering, induces apoptosis via activation-induced cell 
death (AICD). Initiation of AICD requires IL-2 exposure prior 
to secondary TCR stimulation (1). Fas/FasL interaction recruits 
the adaptor protein Fas-associated death domain (FADD), which 
activates caspase-8 and initiates the apoptotic cascade. T  cell 
apoptosis is considered central to lymphocyte homeostasis and 
tolerance induction (1).
PHeNOtYPe AND cHArActeristics OF 
Fas-DeFicieNt Mice
lpr (lymphoproliferation spontaneous mutation) mice deficient in 
Fas show defective AICD of restimulated T cells in vitro. lpr mice 
present lymphadenopathy due to double-negative (DN) T  cell 
(TCR+CD4−CD8−B220+) hyperproliferation and accumulation. 
They also develop lupus-like autoimmune disease, probably due 
to CD4+ T cell hyperactivation. The severity of these symptoms 
depends on genetic background. B6/lpr mice develop anti-DNA 
antibodies and mild, non-lethal glomerulonephritis, whereas lpr 
mice on the MRL background (MRL/lpr) show more pronounced 
autoimmune manifestations, thereby leading to kidney failure 
and death (1); this severe phenotype is a combined result of the 
autoimmune-prone background and the lpr mutation. lpr mice 
of both backgrounds develop severe lymphadenopathy and 
splenomegaly.
The hyperproliferative T  cell phenotype of lpr mice is also 
observed in patients with autoimmune lymphoproliferative 
syndrome (ALPS) (2–4), an autoimmune disease also character-
ized by defective Fas/FasL signaling. ALPS patients are classified 
by distinct disease types, depending on the underlying genetic 
defect (5). The main characteristics of this syndrome are DN 
T  cell accumulation and hyperproliferation, lymphadenopathy 
development, autoimmune manifestations, and increased risk of 
lymphomas.
tHe cONtrOversY Over Fas-
DePeNDeNt t ceLL APOPtOsis IN VIVO
Although lack of Fas-triggered apoptosis in in  vitro-activated 
T cells of lpr mice was initially suggested to be a direct cause 
of lymphadenopathy and lupus-like disease (6), the etiology 
of these symptoms remains enigmatic. While Fas-dependent 
apoptosis has been clearly established and extensively studied in 
IL-2-exposed and -restimulated T cells, in vivo Fas/FasL-induced 
apoptosis and T  cell elimination have been questioned. All 
evidence for the Fas/FasL apoptosis pathway is based essentially 
on in vitro experiments of recurrent T cell activation, and the 
in vivo role of this system thus remains ill defined. For example, 
peptide-induced deletion of T  cells in TCR transgenic mice 
was reported to be Fas dependent in one model, whereas it was 
Fas independent in other settings (7, 8). Superantigen-induced 
T cell deletion is dependent on Fas in some systems but not in 
others, and it was concluded that dissimilar experimental con-
ditions might alter Fas effectiveness (9). Peripheral DN T cells 
appear to depend on Fas for superantigen-induced apoptosis 
(10). In addition, defective AICD was not identified following 
in vivo T cell activation in mice in which Fas was specifically 
deleted in T cells (11). In vivo Fas-dependent apoptosis is thus 
not clearly defined in in vivo systems (1), and the debate con-
tinues as to how Fas deficiency leads to DN T cell accumulation 
and lymphadenopathy development.
This debate was further fueled by research directed toward 
defining whether inactivation of components of the Fas/FasL 
apoptosis system could reproduce the disease-prone lpr phe-
notype. Transgenic mice were produced that overexpress the 
caspase-8 inhibitor CrmA in T  cells, and AICD of these cells 
was efficiently inhibited in vitro (12, 13). The CrmA transgenic 
mice, nonetheless, showed no T  cell abnormalities in  vivo, no 
lymphadenopathy, and no predisposition to autoimmunity 
(12, 13); it was thus suggested that in addition to its role in 
apoptosis, Fas has other functions in the control of in  vivo 
T  cell homeostasis (12). In other studies, mice were rendered 
deficient in the major apoptotic regulators caspase-8 or FADD, 
but again, the lpr in vivo symptoms were not replicated (14, 15); 
instead, both caspase-8 and FADD were shown to be necessary 
for normal T cell proliferation. These studies predicted a pos-
sible Fas association not only to apoptosis but also to T  cell 
proliferation, and it was proposed that the defective in  vitro 
apoptosis of restimulated T  cells might not be related to the 
lpr phenotype (16).
HYPerPrOLiFerAtiON OF ALL lpr 
MOUse t ceLL sUBsets
A critical characteristic of the lpr phenotype is extensive T cell 
hyperproliferation, which is not explained by the defective Fas/
FasL apoptotic system. DN CD4+ and CD8+ T cells hyperprolif-
erate in  vivo (17–19) and memory T  cells (CD44high/CD62Llow) 
expand massively in lymphoid organs. DN lpr T cells were ini-
tially considered inert or anergic cells that accumulate in lymph 
nodes (20, 21). This does not concur with their hyperproliferative 
state or with the fact that they secrete large amounts of inflam-
matory cytokines such as IFN-γ and IL-17 and can be pathogenic 
(22–24). Furthermore, IL-23 is essential for lymphadenopathy 
and DN T cell expansion, as disrupted signaling by this cytokine 
leads to lower numbers of DN T cells (22). The active state of DN 
cells is supported by recent findings that normal programmed cell 
death protein 1-expressing DN cells are pro-inflammatory and 
respond to self-antigens (25, 26) and by their association with 
human lupus (27, 28).
Lymph node lpr DN cells proliferate in vivo at much higher 
rates than CD8+ T  cells (Figure  1A). lpr DN T  cells might 
originate from activated single-positive T  cells that have lost 
the CD8 receptor (29); however, they have a much higher 
proliferation rate than CD8+ cells. Alternatively, it was recently 
argued that lpr DN cells correspond to normal DN T cells with 
inherently increased proliferation than CD4+ or CD8+ T  cells 
(10, 28). Regardless of their origin, DN cells proliferate at much 
higher rates and their homeostasis might be Fas/FasL pathway 
dependent (10, 28).
T  cell hyperproliferation is also observed in patients with 
ALPS (2, 4), an autoimmune disease characterized by defective 
FigUre 1 | In vivo hyperproliferation of lpr t cells is moderated by p21. (A) Increased proliferation of B6/lpr double-negative (DN) and CD8+ T cells compared 
to control B6 cells. Lymph node cells were obtained from mice, which received BrdU in the drinking water for 8 days. FACS analysis was used to identify cell types 
and percentage of proliferating BrdUhi T cells. (B) Effect of a T cell-directed p21 transgene on the proliferation levels of DN and CD8+ T cells from lymph nodes of B6 
and B6/lpr mice, detected by BrdU incorporation as in A. The p21 transgene did not affect the levels of low proliferating DN and CD8+ B6 T cells, while it reduced by 
more than 50% the BrdU uptake by the corresponding B6/lpr cells.
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Fas/FasL signaling or by other genetic defects associated with the 
Fas/FasL pathway. The major features of this syndrome are DN 
T  cell accumulation, lymphadenopathy development, autoim-
munity, and increased lymphoma risk (5).
To explain the lymphoproliferative and autoimmune lpr 
phenotype, we suggested that Fas deficiency also leads to T cell 
proliferation abnormalities (30), a view previously proposed 
based on studies of ALPS patients (4). Indeed, treatment of ALPS 
patients includes drugs that target the activation/proliferation 
aspects of accumulating T cells, such as mycophenolate mofetil 
and sirolimus (rapamycin) (31).
While Fas functions other than apoptosis are well established 
(32), and lpr T cell hyperproliferation appears to be essential for 
development of the lpr phenotype, Fas-deficient apoptosis is still 
considered the prevailing cause of lymphadenopathy and autoim-
munity development in lpr mice.
reDUctiON OF t ceLL 
HYPerPrOLiFerAtiON regULAtes 
LYMPHADeNOPAtHY AND LUPUs 
DeveLOPMeNt iN lpr Mice
To date, no direct evidence has correlated the defective in vitro 
apoptosis of lpr T  cells with in  vivo T  cell hyperproliferation, 
lymphadenopathy, and autoimmune disease in lpr mice. The 
magnitude of hyperproliferation of all T  cell subsets in lpr 
mice and ALPS patients suggests that this abnormality could 
be relevant in the development of lupus and lymphadenopathy.
Recent research from our laboratory addressed this point, 
demonstrating that reduction of lpr T  cell hyperproliferation 
effectively suppressed lymphadenopathy and autoimmune dis-
ease development in these mice (30). In a previous study, T cell 
blasts from ALPS patients with higher responses than controls 
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showed lower p21 expression (4). We therefore overexpressed 
the cell cycle inhibitor p21 in B6/lpr and MRL/lpr mice in a 
T cell-specific manner. p21 is an established negative regulator of 
repeatedly stimulated but not of naïve T cells and regulates CD4+ 
effector/memory T cell expansion (33, 34).
In general, overexpressed p21 diminished in vivo hyperprolif-
eration of DN cells to almost normal levels and greatly reduced 
lymphadenopathy in lpr mice (Figure  1B). p21 also decreased 
CD4+ and CD8+ lpr T cell hyperproliferation and autoimmune 
disease development. Importantly, p21 reduced the activated phe-
notype of these cells as well as that of DN cells and downregulated 
their potential to produce IFN-γ and IL-17. p21 also detained lpr 
T cell hyperactivity, which suggests that p21 regulates activation 
pathways. In fact, p21 suppresses macrophage activation through 
the NF-κB activation pathway (35, 36) and inhibits inflammatory 
cytokine production (35–38) in a cell cycle-independent manner.
Overexpression of p21 had no effect on the in vivo proliferation/
activation of normal background T cells (CD4+, CD8+, and DN) 
(Figure 1B), or their effector/memory T cell expansion. Therefore, 
p21 effects on lpr hyperproliferation and lymphadenopathy are 
not caused by p21 influence on essential normal T cell functions. 
It appears that lack of Fas interferes with the regulation of activa-
tion and proliferation, which is then adjusted by overexpressed 
p21. Recurrent in vitro activation of p21-overexpressing wt and 
lpr T cells showed no effect on apoptosis induction in wt T cells 
and did not restore the defective apoptosis of lpr T  cells. This 
finding indicates that p21 reduced the lpr lymphoproliferation 
without interfering with apoptosis pathways.
p21 thus reduced lpr T cell hyperproliferation, lymphadenopa-
thy, and autoimmune disease development in lpr mice, showing 
that this hyperproliferation is critical for lymphadenopathy and 
lupus-like disease development.
etiOLOgY OF IN VIVO lpr t ceLL 
PrOLiFerAtiON
Whereas T cell hyperproliferation is central to the development 
of lymphadenopathy and autoimmunity in lpr mice, the cause 
of the hyperproliferation/hyperactivation of all lpr T cell subsets 
remains unclear (17–19). Suppression of in vivo lpr T cell hyper-
proliferation by overexpressed p21 indicated that Fas deficiency 
alters regulation of the proliferation machinery in T cells, render-
ing lpr T cells prone to hyperactivation and hyperproliferation. 
This view is further supported by the finding that p21 overexpres-
sion has no effect on proliferation/activation of wt T cells with 
intact Fas/FasL signaling [Figure 1B; Ref. (30)].
The question that arises at this point is whether lpr T cell hyper-
proliferation is an indirect consequence of the Fas deficiency or 
whether Fas has a direct apoptosis-independent antiproliferative 
effect on T cells. Here, we will explore these two ideas.
the Possibility that Deficient Fas/FasL 
Apoptosis Drives lpr t cell 
Hyperactivation and Hyperproliferation
To date, the in  vivo proapoptotic role of Fas on T  cells 
has been tested in various experimental models, but as 
mentioned above, there is no conclusive evidence to sup-
port an in  vivo apoptotic effect for Fas. In the case that Fas 
would play such a role, however, it could be envisaged that 
activated apoptosis-deficient lpr T  cells would accumulate 
(Figure  2, left). After reactivation, this population would 
secrete inflammatory cytokines such as IFN-γ, IL-17, and 
IL-23, and through a feedback mechanism could generate 
an environment that drives lpr T  cell hyperactivation and 
hyperproliferation. Overexpressed p21 could reduce this 
lpr T  cell hyperproliferation. Nonetheless, as the in  vivo 
proapoptotic Fas/FasL effect remains unclear, the view that 
lpr T cell hyperproliferation is an indirect effect of deficient 
apoptosis remains hypothetical.
the Fas/FasL system As an Attenuator of 
t cell Activation and Proliferation
A number of in  vitro studies support a role for Fas/FasL in 
the regulation of T  cell activation and proliferation. While in 
naïve T  cell activation, Fas acts as a costimulatory molecule, 
in preactivated cells, the FasL/FasL interaction has the oppo-
site effect and appears to inhibit T  cell activation. Suggestive 
evidence for an in  vivo Fas/FasL role as a negative regulator 
of T  cell activation is derived from lpr mice that overexpress 
p21 in T  cells, as high p21 levels controlled lpr T  cell acti-
vation and proliferation as well as autoimmunity and lym-
phadenopathy. Here, we discuss and evaluate this facet of the 
Fas/FasL system.
The Dual Role of Fas in Regulating Naïve T Cell 
Activation
Experimental evidence from primary activation of Fas- and FasL-
deficient T cells showed a role for Fas as a costimulatory molecule 
in naïve T  cell activation (39), and other studies analyzed the 
mechanism of this costimulatory Fas effect (40).
In contrast to the role of Fas/FasL as enhancer of T  cell 
activation, high-dose FasL inhibits TCR-dependent activation of 
human peripheral cells or naïve T cells (41, 42). It appears that 
FasL has an inhibitory effect on T cell activation only at high con-
centrations, while at low concentration, it acts as a costimulatory 
factor. The mechanisms of FasL interference with T cell activation 
and proliferation are reviewed by Paulsen and Jansen and Brint 
et al. (40, 43).
As large amounts of FasL were used in experiments that 
showed the inhibitory effect of Fas/FasL on T  cell activation, 
it might be argued that the results imply a non-physiological 
effect of the Fas/FasL system. These findings nonetheless 
provide a basis for the hypothesis that Fas/FasL interactions 
inhibit in vivo activation and proliferation of T cells in certain 
conditions.
Fas Triggering Reduces the Response  
of Activated T Cells
Experiments using FasL treatment indicate a role for Fas/FasL 
signaling in naïve T  cell activation and proliferation, as com-
mented above. Previously activated T  cells are also sensitive 
to Fas signaling, which reduces their activation and expansion 
FigUre 2 | Pathways that could produce the in vivo hyperproliferation of lpr t cells. Left: Fas-deficient T cells that fail to undergo apoptosis might acquire 
an indirect increased capacity for proliferation, enhanced by inflammatory cytokines that create a feedback loop and result in hyperproliferating lpr T cells. p21 
overexpression inhibits hyperproliferation of these cells, which reduces lymphadenopathy. Right: Fas-deficient T cells show a hyperproliferative phenotype due to 
lack of Fas, which after interacting with Fas ligand (FasL), has a direct regulatory effect on activation/proliferation. These hyperactivated lpr T cells accumulate in 
lymph nodes. p21 overexpression reduces hyperactivation/proliferation of lpr T cells, and lymphadenopathy development is minimal.
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potential. Signaling through Fas elicits antiproliferative effects, 
a finding first reported by the Tsokos laboratory in 1995 (44). 
In that study, Fas cross-linking inhibited subsequent anti-CD3 
activation of human IL-2-dependent T  cells. The same group 
confirmed this concept using Jurkat T cells (45). In a later study 
(4), Fas binding of human T cell blasts reduced their prolifera-
tion with a concomitant increase in p21, a finding that directly 
associates p21 with the antiproliferative mechanism of the Fas/
FasL system. These studies reinforce the view that the Fas/FasL 
system attenuates proliferation, although Fas cross-linking 
in vitro could entail questions regarding the physiological rel-
evance of these data.
Defective Fas/FasL Signaling Leads to lpr T Cell 
Hyperactivation and Is Counteracted by p21 
Overexpression
One of the major autoimmune characteristics of lpr mice is 
hyperactivation of the immune response and specifically, of 
T  cells. Use of lpr-cREL−/− mice (46) showed that lupus-like 
disease depends on immune response activation by c-REL, a 
component of the NF-κB system, whereas absence of NF-κB1 
(p65) in lpr mice led to reduced lymphadenopathy. These data 
argue that hyperactivation is essential for lpr T cell hyperprolif-
eration and corroborate previous results showing that reduction 
in DN cell activity leads to reduced lymphadenopathy (17).
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Here, we propose a potential Fas/FasL role in negative regula-
tion of T  cells repeatedly stimulated by autoantigen that could 
control autoimmunity independently of the classical role of this 
system in in vitro T cell apoptosis. This possibility is reinforced 
by the abovementioned studies in which FasL treatment of T cells 
reduced their activation and proliferation capacity. This view 
would concur with the development of hyperactivated T  cells, 
whose hyperproliferation leads to their accumulation in the 
lymphoid organs of lpr mice.
In the case of p21 overexpression in lpr mouse T  cells, it 
can be considered that p21 directly suppresses the deregulated 
activation of lpr T cells. This would adjust the hyperproliferative 
state of lpr T cells and inhibit development of autoimmunity and 
lymphadenopathy (Figure  2, right). This view of a direct p21 
effect on lpr T cell activity is supported by in vivo experiments 
in which p21 overexpression by lpr T  cells reduced activation 
marker expression and IFN-γ production, which finally reduced 
proliferative capacity (30). In in  vitro experiments, overex-
pressed p21 was detected shortly after secondary stimulation 
and coincided with reduction of T cell activation. These results 
link p21 to regulation of T cell activation, as p21 had no effect on 
Fas/FasL apoptosis. p21 overexpression leads to early reduction 
of extracellular signal-regulated kinase activity (30), a finding 
that further supports a role for p21 in controlling recurrent lpr 
T cell activation. This p21 function is further reinforced by stud-
ies showing that p21 attenuates NF-κB-dependent macrophage 
activation (35, 36). Unpublished data from our laboratory 
indicate a role for normally expressed p21 in T cell activation 
after secondary stimulation. Evidence that p21 regulates T cell 
activation after secondary apoptosis would further strengthen 
the view that lack of Fas/FasL signaling leads directly to T cell 
hyperactivation.
By introducing the idea that defective Fas/FasL signaling 
generates T  cell hyperactivation/hyperproliferation in lpr mice 
independent of the apoptotic defect, we supply a model that 
explains autoimmunity and lymphadenopathy in these mice. It is 
our hope that this perspective will prompt research that clarifies 
the etiology of the lpr mouse phenotype and explains how Fas/
FasL interaction modulates T cell activation and proliferation.
eMergiNg vieWs
Although Fas is considered a central molecule in T cell apoptosis, 
and the in vitro apoptosis effects of the Fas/FasL pathway have 
been studied extensively, the influence of this system on the lpr 
mouse phenotype remains unclear. With the exception of some 
recent studies, research in T  cells has shifted mainly to other 
molecules that control homeostasis. Most of our understanding 
of Fas/FasL is based on analyses in other tissues and systems, 
and the role of Fas in lymphadenopathy and autoimmunity has 
remained undefined. We thus consider it imperative to determine 
how Fas contributes to T cell-driven autoimmunity, since MRL-
lpr lupus-like disease is a prevalent model for autoimmunity 
studies. In this perspective, we explain how p21-based reduction 
in lpr T cell hyperactivation led us to link lpr T cell hyperactiva-
tion to lymphadenopathy and lupus development in lpr mice and 
ALPS patients. This hypothesis evokes the exciting possibility that 
impaired Fas/FasL signaling could control lpr T  cell activation 
and proliferation directly. Further research is needed to address 
this prospect and draw to a close the debate as to how defective 
Fas apoptosis leads to the lpr phenotype. Perhaps, recent mecha-
nistic evidence showing that Fas drives distinct activities (47, 48) 
will help to define the diverse Fas pathways involved in T  cell 
function.
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